Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus

Table 1

Baseline characteristics in the 118 study patients.

	Treated ()	Untreated ()	value
Age (years)^a			<0.0001
HbA1C (%)^a			NS
Males/females	26/33	25/34	NS
Whites/blacks	19/40	29/30	NS
BMI (kg/m^2)^a			NS
Cirrhosis/no cirrhosis	27/32	26/33	NS
Viral load ()^a			NS
HCV genotype 1/2/3/4	55/2/1/1	46/10/3/0	0.034^b
Serum ALT (U/L)^a			NS
Serum AST (U/L)^a			NS
Inflammation: A0-A1/A2-A3^c	35/24	32/27	NS
Fibrosis: F0-F2/F3-F4^d	32/27	33/26	NS
Oral medication	13	33	NS
Insulin	6	19	NS
Both	25	7	NS
Diet modification	15	0	—

BMI: body mass index; HbA1C: hemoglobin A1C level (%); HCV: hepatitis C virus; NS: value not statistically significant (). ^a. ^bGenotype 1 vs. non-1. ^cInflammation (A) score on liver biopsy ranging from A0 to A3 (see text). ^dFibrosis (F) score on liver biopsy ranging from F0 to F4 (see text).